Figure 3
Systemic administration of MHP1-AcN inhibited IMQ-induced IL-6, IL-23 and IL-17A expression. MHP1-AcN (100 µg/mouse) or saline was systemically administered by daily subcutaneous injection at a distant site from IMQ application. Mice were sacrificed at 32 h or d9 in two independent experiments. Dorsal skin samples where IMQ was applied and serum samples were collected. (A) The mRNA expression of Il6, Il23, and Il17a at 32 h and d9 in dorsal skin was analyzed by real-time PCR. (B) Serum IL-6, IL-23, and IL-17A levels at 32 h and d9 were measured by ELISA. *P < 0.05, **P < 0.01 vs. the saline-treated IMQ group. 32 h: N = 3 per normal group; N = 4 per saline-treated IMQ group; N = 4 per MHP1-AcN-treated IMQ group, d9: N = 3 per normal group; N = 4 per saline-treated IMQ group; N = 4 per MHP1-AcN-treated IMQ group. All values are expressed as the mean with SEM.
